Tag: Dr Jayson Dallas
Nestlé to Acquire Aimmune Therapeutics
Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment.
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development...
“In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune’s global leadership in the evolving therapeutic landscape of food allergy treatments.”
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...
AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final...
Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community.
Aimmune Announces US FDA Advisory Committee Meeting Date for AR101 for...
The FDA will review Aimmune's Biologics Licence Application for AR101 on September 13, 2019.
European Phase 3 Trial of AR101 Peanut OIT Candidate Meets Primary...
Company Intends to Submit European MAA in Mid-2019.
US FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut...
If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition.
Aimmune Submits FDA Application to Offer AR101 for the Treatment of...
“We have requested FDA Priority Review and look forward to working with the agency to bring what could be the first approved treatment in food allergy to patients as quickly as possible.”
Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate
AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
